Syngene targets growth with global trial and biotech funding

10 Nov 2025 · 16:13 ISTafter close1 source ↓written by the desknot a recommendation

Syngene International has secured its first global Phase 3 clinical trial, collaborating with a US biotech firm to recruit patients in India and the US. This milestone signals a strategic growth area for the company. Despite strong research services, near-term profitability is impacted by depreciation from its new biologics facility in Bengaluru.

Not investment advice. For informational purposes only.

OI Charts is not a SEBI-registered investment adviser or research analyst. This bulletin was written by the OI Charts desk from the public sources listed here. It is commentary on market conditions, not a basis for any investment decision and not a recommendation to buy or sell any security. Prices as of 10 Nov 2025, 16:13 IST.

Sourcesnews.google.com

SYNGNE
Pharma
Biotech

28 JanSyngene focuses on capex amid Q3 biologics challengesMediumSyngene International reported a softer Q3 due to a large biologics programme affecting revenue and margins. Despite this, the company is committed to capital expenditure and has extended its partnership with Bristol Myers Squibb until 2035.
1 OctAjanta Pharma promoters pledge shares for ₹3,873 crore debtMediumAjanta Pharma's promoters pledged 26,21,067 shares to secure ₹3,873 crore in debt instruments, comprising ₹3,373 crore from Lenexis Foodworks and ₹500 crore from Inspira Realty 2. This move may affect liquidity and investor sentiment.
29 SeptAnupam Rasayan completes Bliss GVS Pharma acquisitionHighAnupam Rasayan India has acquired a 48.2% stake in Bliss GVS Pharma at ₹299 per share, funded by a ₹300 crore loan and ₹1,450 crore from investors. This strategic move enhances its portfolio in pharmaceuticals.
29 SeptNifty 50 declines as bond yields rise and risks escalateHighThe Nifty 50 closed at 22,780.25, down 1.56%, as 10-year G-Sec yields rose to 7.17%. The index remains below its 50-day SMA, indicating weak momentum amid geopolitical risks and potential RBI rate hikes.
29 SeptStocks poised to gain from falling rupeeMediumAs the rupee depreciates, Indian stocks with foreign revenue streams may benefit. Indegene is highlighted for its potential in the life sciences sector, capitalizing on the current market stress driven by oil prices and geopolitical risks.
28 SeptSanofi Healthcare acquires 15.2% stake in Sanofi IndiaHighSanofi Healthcare India acquired a 15.2% stake in Sanofi India for ₹1,068 crore, purchasing 35 lakh shares at ₹3,052 each. Hoechst GmbH's holding in Sanofi India fell to 45.17% after the transaction.

Syngene targets growth with global trial and biotech funding

Related